This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation

This study has been completed.
Information provided by:
Movetis Identifier:
First received: January 8, 2008
Last updated: May 28, 2008
Last verified: January 2008

The purpose of the study is to determine whether prucalopride is safe and effective in patients with chronic idiopathic constipation.


At all doses administered prucalopride given once daily for 4 weeks is safe and well tolerated in patients with chronic idiopathic constipation.

Condition Intervention Phase
Constipation Drug: prucalopride Drug: 2 mg prucalopride Drug: 4 mg prucalopride Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation

Resource links provided by NLM:

Further study details as provided by Movetis:

Primary Outcome Measures:
  • Evaluation of the optimal dose of R093877 for the treatment of chronic idiopathic constipation by comparing the efficacy and safety of 0.5 mg, 1 mg, 2 mg, and 4 mg of R093877 versus placebo given orally once daily for 4 weeks. [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Evaluation of the effects of R093877 on symptoms associated with idiopathic constipation [ Time Frame: 4 weeks ]

Enrollment: 313
Study Start Date: September 1996
Study Completion Date: June 1997
Primary Completion Date: June 1997 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
0,5 mg prucalopride
Drug: prucalopride
0,5 mg once daily
Other Name: Resolor
Active Comparator: 2
1 mg prucalopride
Drug: prucalopride
1 mg once daily
Other Name: Resolor
Active Comparator: 3
2 mg prucalopride
Drug: 2 mg prucalopride
2 mg once daily
Other Name: Resolor
Placebo Comparator: 5
Placebo arm
Other: Placebo
placebo once daily
Active Comparator: 4
4 mg prucalopride
Drug: 4 mg prucalopride
4 mg once daily
Other Name: Resolor

Detailed Description:

This was a double-blind, placebo-controlled, randomized, parallel group, multicentre, Phase II, dose comparison trial, in which 313 subjects, with a history of chronic idiopathic constipation were enrolled. The trial was conducted in three phases:

  1. a 4-week drug-free run-in phase,
  2. a 4-week double-blind (DB) phase during which subjects were treated with R093877 (0.5 mg, 1 mg, 2 mg, or 4 mg capsule) or matching placebo once daily, prior to breakfast,
  3. a 4-week drug-free run-out phase (RO).

To qualify for the run-in phase (Visit 1, Week 1) subjects had to have experienced, for at least 3 months, 2 or less spontaneous, bowel movements (SBM)/week with the occurrence of lumpy (scyballae) and/or hard stools, a sensation of incomplete evacuation for at least a quarter of their stools, or straining during defecation at least a quarter of the time.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant female outsubjects between 18 and 70 years of age.
  • Documented history of constipation. The subject reports 2 or less SCBM/week with the occurrence of one or more of the following for at least 3 months before selection visit:

    • lumpy (scyballae) and/or hard stools at least a quarter of the stools;
    • sensation of incomplete evacuation following at least a quarter of the stools; or
    • straining at defecation at least a quarter of the time.

These criteria were only applicable for spontaneous, complete bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent.

  • Normal inhibition pattern of the external anal sphincter during straining, i.e., relaxation of the m. puborectalis and a distal displacement of the rectal canal (digital examination and/or electromyographic and/or manometric evidence was acceptable).
  • The subject's constipation was functional, i.e., idiopathic.
  • Written informed consent, signed by the subject and/or legal guardian and by the investigator.
  • Subject were available for follow-up during the trial period, as determined in the protocol.

Exclusion Criteria:

  • Subjects in whom constipation was thought to have been drug-induced.
  • Subject who suffered from types/causes of constipation other than idiopathic constipation, i.e.,presence of secondary causes of constipation including:

    • Endocrine disorders
    • Metabolic disorders
    • Neurologic disorders including:
  • Irritable bowel syndrome.
  • Subjects with congenital megacolon/megarectum or a diagnosis or pseudo-obstruction.
  • History of previous abdominal surgery (excluding hysterectomy, surgery for Meckel's diverticle,appendectomy, cholecystectomy, inguinal hernia repair, splenectomy, nephrectomy, fundoplication)thought to have been the primary cause of constipation.
  • Known or suspected organic disorders of the large bowel (i.e., obstruction, carcinoma, or inflammatory bowel disease). -Subjects with active proctological conditions thought to have been responsible for the constipation.
  • Subjects with ECG abnormalities including:

    • 2nd or 3rd degree AV block;
    • prolonged QTc intervals (> 460 msec); or
    • bradycardia (< or equal to 60 bpm).
  • Subjects who were receiving concomitant medication which could cause QT prolongation
  • Subjects on potassium-wasting diuretics.
  • Subjects with known illnesses or conditions such as:

    • severe cardiovascular or lung disease,
    • neurologic or psychiatric disorders (including active alcohol or drug abuse),
    • cancer,
    • AIDS, or
    • other gastrointestinal or endocrine disorders.
  • Subjects with impaired renal function
  • Subjects with a serum amylase, AST (SGOT), or ALT (SGPT) concentration >2 times the normal limit.
  • Subjects with clinically significant abnormalities of hematology, urinalysis or blood chemistry.
  • Females of childbearing potential without adequate contraceptive protection during the trial. Oral
  • Females who were pregnant or lactating.
  • Subjects who received an investigational drug in the 30 days preceding the run-in phase of this trial.
  • Subjects who were unable or unwilling to return for required follow-up visits.
  • Subjects whose reliability or physical state hindered adequate participation in a clinical trial.
  • Subjects who had polyps discovered during the screening colonoscopy that were untreated (i.e., by polypectomy). Subjects who had polyps during the screening colonoscopy that were treated by polypectomy were allowed to enter the trial after the 4-week healing period. Any subject with polyp(s)documented to contain an invasive carcinoma (Duke's B or greater) was excluded from this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00596596

Sponsors and Collaborators
Principal Investigator: Trent Nichols, MD Hanover General Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Renate Specht Gryp, Movetis Identifier: NCT00596596     History of Changes
Other Study ID Numbers: PRU-USA-3
Study First Received: January 8, 2008
Last Updated: May 28, 2008

Keywords provided by Movetis:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on August 17, 2017